

ANIMAL WELFARE & ETHICAL REVIEW BODY

Minutes: 1:30pm, Tuesday 15th June 2021, Online meeting

	Items.	AWERB Outcome
1	Attendance:	
2	Minutes of the last meeting.	
2.1	Up to date and sent on to ASU Management Board.	Complete
3	Matters arising from the notes of previous meeting (18 th May 2021)	
3.1	3.1 Formalising draft PPL application review deadlines and production of guidance documents.	Ongoing
3.2	3.2 internal Tissue Sharing Network platform shared with AWERB members. Etiquette Document drafted and to be circulated for review.	Ongoing
3.3	3.3 Structure of AWERB continues to be discussed at ASU Management Board (ASUMB).	Ongoing
3.4	3.4 Future AWERB auditing of techniques.	Ongoing
3.5	3.7 Explore potential updated options for facilitating anonymous whistleblowing.	Ongoing
4	Chair's Report	
4.1	Thanks to all involved in organising the GW4 3Rs Symposium.	
5	NTCO Report.	
5.1	Handling training and animal history check incorporated into Training and Competency Report	
5.2	NVS walk-arounds now recorded on online system	
5.3	Allied large animal research centre induction records added to online system.	

5.4	Training and competency records checked for June PPL and PPL Amendment applicants.	
6	NIO Report.	
6.1	Selection of relevant upcoming 3Rs webinars and CPD opportunities circulated to PPL holders, PIL holders and ASU technicians.	
6.2	Concordat on Openness attended, notes available to AWERB members.	
6.3	Plans for content on ASU Intranet.	
6.4	New initiatives to provide support and guidance for PPL writing.	
6.5	Surveys prepared for ASU Staff and academic colleagues.	
7	NVS Report.	
7.1	No animal welfare issues to report.	
8	NACWO reports.	
8.1	First NACWO Team meeting held.	
8.2	Meeting attended to contribute ideas to refine large animal study.	
8.3	Steady breeding seen at breeding facility.	
8.4	No welfare concerns from zebrafish aquarium or satellite animal units.	
9	Project Licences – New Applications.	
9.1	<p>PPL.1June21 Aims: To investigate immunological mechanisms involved in joint inflammation in arthritis as well as co-existing inflammation in other tissues and to evaluate immune-modulating drugs as novel treatments for inflammatory arthritis and its co-morbidities.</p> <p>Harms: Project will involve the use of pain models with most animals used in a short-term pain model. There is also a longer term and more generalised inflammatory model which is expected to generate more systemic illness.</p>	Approved subject to clarifications to be verified by NVS

	<p>Assessments of the animal model will include studies requiring repeated general anaesthesia with some animals potentially receiving up to 30 recovery anaesthetics. Some models can be given analgesia but as the inflammatory process is part of the scientific objectives, this will not be used for all animals.</p> <p>Benefits: The project will generate knowledge gain relating to the inflammatory processes which are related to arthritis and potential new targets to modify disease in the future. The benefits in the short to medium term will enhance knowledge but in the longer term, these may identify new treatment approaches and ultimately new therapies.</p> <p>Discussion:</p> <ul style="list-style-type: none"> • Future translational applications • Historical refinements • Sequence of disease progression • Use and forms of anaesthesia and analgesia • Number of recovery anaesthetics and their justification • Scoring system for monitoring • Sex of experimental animals 	
10	Project Licences – Amendments.	
10.1	PPLAmend.2May21 Resubmission	Approved subject to clarifications, to be verified by NVS
	Discussion: <ul style="list-style-type: none"> • Additional injection route under non-recovery anaesthesia only. 	
10.2	PPLAmend.3May21. Resubmission.	Approved subject to clarifications, to be verified by NVS
	Discussion: <ul style="list-style-type: none"> • Provided additional details outlining experimental design. • Monitoring schedule 	
11	Project Licence Reviews	
11.1	Mid Term Reviews.	
11.1.1	MTR1.June21 Drug delivery to the brain for cancer and Parkinson’s disease models. <ul style="list-style-type: none"> • Direct translational impact. • COVID 19 pandemic has decreased work. 	Approved

	<ul style="list-style-type: none"> Publications resulting from work. 	
11.2	Home Office Retrospective Reviews. (None)	
11.3 11.3.1	Final Reviews. (None)	
12	Report on Non-Regulated Projects UIN and VIN applications.	
12.1	<p>Non-Regulated Projects – UINs</p> <p>Reviewed: UIN.1-6 AWERB approved: UIN.1-6 AWERB approved pending clarifications: AWERB did not yet approve:</p>	Secretary to inform
12.1.1	UINs to note: (None)	
12.1.1.1	UIN.4 Only those with up-to-date Schedule 1 records are permitted to work under this UIN.	
12.2	<p>Non-Regulated Projects – VINs.</p> <p>Reviewed: VIN.1-5 AWERB approved: VIN.1-3 & 5 AWERB approved pending clarifications: VIN.4 AWERB did not yet approved: None.</p>	Secretary to inform
12.2.1	VINs to note:	
12.2.1.1	VIN.4: Evidence required that this process is commonly practiced across UK dairy farms as part of routine veterinary care.	
13	Non-Regulated Projects - UIN and VIN amendments	
13.1	VIN.Amend.1: Approved subject to editing of relevant authors and justification of saliva use.	
14	AWERB Hub. (None)	
16	For Information.	

	(None)	
17	Any Other Business.	
17.1	Proposed 2021-22 AWERB dates	Approved
17.2	Antibody Sourcing ethical policy for local company	
17.3	NVS requires ring-fenced time to write the ASU Service Licence.	
18.	Dates of Next Meetings (Online until further notice): Tuesday 20th July 2021	